Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role

Moftah, Moayed Ben; Eswayah, Asma

doi:10.1089/adt.2021.090

Cited by 6 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanisms by which hydroxyurea possibly modulates the clinical course of COVID-19 are not fully elucidated, but it is postulated that the substance diminishes levels of inflammatory cytokines and lowers activation of neutrophils and endothelial adhesion molecules, also reducing the inflammatory cascade ( 59 , 81 ). Due to its apparent anti-inflammatory and immunomodulatory effects, whether directly or indirectly (by fetal hemoglobin synthesis), some experts even argue that the drug can be repurposed to treat COVID-19 in people without sickle cell disease ( 116 , 117 ), thereby supporting the hypothesis that it has protective effects on sickle cell patients.…”

Section: Discussionmentioning

confidence: 99%

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

et al. 2023

View full text Add to dashboard Cite

Sickle cell disease is the most common hemoglobinopathy among humans. As the condition promotes susceptibility to infections, chronic inflammation, and hypercoagulability disorders, several international agencies have included individuals with this disease in the COVID-19 risk group for severe outcomes. However, available information about the subject is not properly systematized yet. This review aimed to understand and summarize the scientific knowledge about the impact of SARS-CoV-2 infection in patients with sickle cell disease. Searches were performed in the Medline, PubMed, and Virtual Health Library databases based on descriptors chosen according to the Medical Subject Headings. We analyzed studies published between 2020 and October 2022, developed with qualitative, quantitative, or mixed methodology, and written in English, Spanish, or Portuguese. The search resulted in 90 articles organized into six categories. There is disagreement in the literature about how different aspects related to sickle cell disease, such as chronic inflammation status, hypercoagulability, hemolytic anemia, use of hydroxyurea, and access to medical care interference with the clinical course of COVID-19. These topics deserve further investigation. It is evident, however, that the infection may manifest in an atypical way and act as a trigger for the development of sickle cell-specific complications, such as acute chest syndrome and vaso-occlusive crises, conditions that are associated with great morbidity and mortality. Therefore, healthcare professionals must be aware of the different forms of presentation of COVID-19 among these individuals. Specific guidelines and therapeutic protocols, as well as public policies for sickle cell individuals, must be considered.Systematic review registrationThis review (https://doi.org/10.17605/OSF.IO/NH4AS) and the review protocol (https://osf.io/3y649/) are registered in the Open Science Framework platform.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In addition, in a cohort study, gemcitabine reduced SARS-CoV-2 infection in cancer patients [228]. Hydroxyurea, an antimetabolite treating sickle cell anemia, has anti-inflammatory and immunomodulatory effects and was expected to apply well in COVID-19 [229].…”

Section: Potential Drugs To Cure Severe Covid-19 Patientsmentioning

confidence: 99%

Analysis of protein-protein interaction network from leukocyte transcriptomic profiles in severe COVID -19 patients

Sagulkoo

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) still provides global public health issues although several vaccines and antiviral agents have been developed. Some patients experience severe conditions needed medical intensive care, and some are dead due to the failure of treatments. Therefore, identifying the key genes and underlying molecular mechanisms is necessary to discover precisely targeted drugs. Analysis of protein-protein interaction (PPI) networks provides invaluable information to find disease mechanisms and effective alternative drugs. Hence, PPI network analysis based on leukocyte transcriptomic profiles of severe COVID-19 collected from Gene Expression Omnibus (GEO) DataSets was proposed for this study. A network diffusion method called Laplacian heat diffusion (LHD) algorithm was performed to construct an immune-related PPI network (IPIN). Furthermore, several network centrality measurements can identify 23 key genes from the IPIN. Subsequently, drug-gene interaction networks were constructed using database searching based on the key genes. There were 5 candidate drugs having the potential effect of interacting with the key genes. To find additional key genes and candidate drugs, two different leukocyte transcriptomic datasets were combined for the common PPI network construction. Centrality measurement and survival analysis were used to find and validate the further key genes. The analysis revealed 4 common key genes. The drug-gene interaction and molecular docking technique provided 2 further candidate drugs that interacted with the key genes. Additionally, miRNA-mRNA regulatory networks were built based on the PPI network to recognize 5 novel biomarkers for severe COVID-19 prediction. In conclusion, PPI network analysis can discover candidate biomarkers and drugs to predict�and treat severe COVID-19 patients.�

show abstract

Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19

Lykhmus,

Kalashnyk,

Sullivan

et al. 2023

Journal of Neuroimmunology

View full text Add to dashboard Cite

Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role

Cited by 6 publications

References 80 publications

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review

Analysis of protein-protein interaction network from leukocyte transcriptomic profiles in severe COVID -19 patients

Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19

Contact Info

Product

Resources

About